-
2023-507402-13-00
5
2024-04-03
Multiple myeloma
-
2022-501606-35-01
11
2024-02-21
Platinum-sensitive epithelial ovarian, fallopian tube, or primary
peri
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2022-502503-30-00
5
2022-12-15
Acute lymphoblastic leukemia
-
2023-507518-28-00
5
2022-09-13
Acute myeloid leukemia
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan
-
2022-503012-16-00
5
2022-07-20
Patients on treatment with Factor Xa Inhibitor needing for an urgent i
-
2023-506414-46-00
5
2022-04-22
High risk patients defined as having at least one of the following ris
-
2025-523914-10-00
6
2026-04-30
Critical illness
-
2024-516544-26-00
4
2026-03-30
acute ischemic stroke
-
2024-518210-81-00
5
2026-03-18
Advanced Hepatocellular Carcinoma
-
2025-521762-99-00
5
2026-03-09
acute ischemic stroke
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2022-500676-59-00
4
2025-12-18
EBV-positive nasopharyngeal carcinoma
-
2025-522860-34-00
5
2025-12-16
Chronic lymphocytic leukemia (CLL)
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2023-509861-19-01
4
2025-09-30
High-grade B-cell lymphoma (HGBL)
-
2024-519152-82-00
5
2025-09-03
Relapsed/Refractory Follicular Lymphoma
-
2024-515561-34-01
6
2025-08-04
Acute ischemic stroke with recent ingestion of direct oral anticoagula
-
2023-510294-34-00
5
2025-06-12
small lymphocytic lymphoma (SLL)
-
2023-508076-11-00
5
2025-04-01
Colon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan w
-
2023-510323-30-00
5
2025-01-24
First-line treatment of recurrent or metastatic PD-L1+ head and neck s
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer